nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”nodgo-1022Research ArticleПО МАТЕРИАЛАМ КОНГРЕССА РОДОГBASED ON MATERIALS FROM THE CONGRESS OF RSPOHРезультаты сателлитного симпозиума «Что нам стоит дом построить? Иммунотерапия острого лимфобластного лейкоза в детской практике», состоявшегося 23 ноября 2023 г. в рамках IV объединенного Конгресса РОДОГ «Актуальные проблемы и перспективы развития детской онкологии и гематологии в Российской Федерации – 2023»Results of the satellite symposium “What does it cost us to build a house? Immunotherapy of acute lymphoblastic leukemia in pediatric practice”, held on November 23, 2023 within the framework of the IV Joint Congress of RSPOH “Actual problems and prospects for the development of pediatric oncology and hematology in the Russian Federation – 2023”КиргизовК. И.KirgizovK. I.ПаинаО. В.PainaO. V.БронинГ. О.BroninG. O.2024130520241117274Copyright © Киргизов К.И., Паина О.В., Бронин Г.О., 20242024Киргизов К.И., Паина О.В., Бронин Г.О.Kirgizov K.I., Paina O.V., Bronin G.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/1022
.
.
ReferencesBenjamin J.E., Stein A.S. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3):142–56. doi: 10.1177/2040620716640422.Benjamin J.E., Stein A.S. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7(3):142–56. doi: 10.1177/2040620716640422.Queudeville M., Ebiger M. Blinatumomab in pediatric acute lymphoblastic leukemia – from salvage to fi rst line therapy (a systematic review). J Clin Med. 2021;10(12):2544. doi: 10.3390/jcm10122544.Queudeville M., Ebiger M. Blinatumomab in pediatric acute lymphoblastic leukemia – from salvage to fi rst line therapy (a systematic review). J Clin Med. 2021;10(12):2544. doi: 10.3390/jcm10122544.Rallis K.S., Hillyar C.R.T., Sideris M., Davies J.K. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecifi c T-Cell Engagers (BiTEs). Anticancer Res. 2021;41(3):1123–41. doi: 10.21873/anticanres.14870.Rallis K.S., Hillyar C.R.T., Sideris M., Davies J.K. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecifi c T-Cell Engagers (BiTEs). Anticancer Res. 2021;41(3):1123–41. doi: 10.21873/anticanres.14870.Majhail N.S., Mau L.W., Chitphakdithai P., Denzen E.M., Joff e S., Lee S.J., LeMaistre C.F., Loberiza F., Parsons S.K., Repaczki-Jones R., Robinett P., Rizzo J.D., Murphy E., Logan B., Le-Rademacher J. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplant. 2020;55(5):906–17. doi: 10.1038/s41409-019-0748-1.Majhail N.S., Mau L.W., Chitphakdithai P., Denzen E.M., Joff e S., Lee S.J., LeMaistre C.F., Loberiza F., Parsons S.K., Repaczki-Jones R., Robinett P., Rizzo J.D., Murphy E., Logan B., Le-Rademacher J. Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplant. 2020;55(5):906–17. doi: 10.1038/s41409-019-0748-1.Gratwohl A., Baldomero H., Aljurf M., Pasquini M.C., Bouzas L.F., Yoshimi A., Szer J., Lipton J., Schwendener A., Gratwohl M., Frauendorfer K., Niederwieser D., Horowitz M., Kodera Y.; Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24. doi: 10.1001/jama.2010.491.Gratwohl A., Baldomero H., Aljurf M., Pasquini M.C., Bouzas L.F., Yoshimi A., Szer J., Lipton J., Schwendener A., Gratwohl M., Frauendorfer K., Niederwieser D., Horowitz M., Kodera Y.; Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24. doi: 10.1001/jama.2010.491.
The authors declare that there are no conflicts of interest present.